C
프레스티지바이오로직스
334970KOSDAQ의약품 제조업48.3 / 100
Reference Date: 2026-06-10
Financial Score10.0 / 40
News Sentiment21.3 / 25
Momentum5.0 / 20
Disclosure12.0 / 15
AI Analysis: ROE is below the industry average, Operating Profit is on a declining trend. Declined 14.4% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Prestige BioLogics specializes in contract manufacturing of advanced biopharmaceuticals for domestic and international pharmaceutical companies, offering customized services throughout the development process via its CDEMO business model. In the first half of 2024, antibody drug sales accounted for 68% of total revenue.
Number of Employees
279people
Average Salary
42.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 11.934.0Point
PBR
1.03Industry Average 0.892.5Point
Higher than industry avg (caution)
ROE
-26.56Industry Average 4.010.0Point
Well below industry avg
Debt Ratio
24.16Industry Average 12.430.5Point
1.9x industry avg (risky)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲251.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼26.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -30.4% (improving, 2yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive프레스티지바이오로직스, 24억원 원료의약품 위탁생산계약 체결
프레스티지바이오로직스가 원료의약품 위탁생산 계약 체결로 인해 긍정적인 재무적 성과와 성장 가능성을 보여주었다.
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 1,797Won52-week high 4,84052-week low 1,772
1-month return1.0Point
1m -14.43% (falling)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 1Neutral 1Negative 0
- Positive단일판매ㆍ공급계약체결2026-05-15
- Neutral분기보고서 (2026.03)2026-05-15